+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Reducing the risk of left ventricular hypertrophy in kidney transplant recipients: the potential role of mammalian target of rapamycin



Reducing the risk of left ventricular hypertrophy in kidney transplant recipients: the potential role of mammalian target of rapamycin



Transplantation Proceedings 41(6 Suppl.): S3-S5



Persistence of left ventricular hypertrophy (LVH) following renal transplantation is associated with unfavorable outcomes in renal transplant recipients. This review presents clinical data on LVH after renal transplantation and the role of antihypertensive therapy, especially ACE inhibitors, to reduce left ventricular mass, as well as the effects of interactions between antihypertensive medications acting on the renin-angiotensin system and immunosuppressive agents to regress LVH among renal transplant recipients. The effectiveness of sirolimus (SRL) to reduce posttransplantation LVH is also discussed in light of both animal model studies and 2 clinical trials in transplant recipients that showed the efficacy of this immunosuppressive agent to treat LVH in both kidney and heart transplant recipients.

(PDF emailed within 0-6 h: $19.90)

Accession: 055431109

Download citation: RISBibTeXText

PMID: 19651293

DOI: 10.1016/j.transproceed.2009.06.091


Related references

Regression of left ventricular hypertrophy in kidney transplant recipients: the potential role for inhibition of mammalian target of rapamycin. Transplantation Proceedings 42(9 Suppl.): S41-S43, 2011

Cardiovascular risk in kidney transplant recipients receiving mammalian target of rapamycin inhibitors. Transplantation Proceedings 43(8): 2967-2969, 2012

Risk Factors Associated With Mammalian Target of Rapamycin Inhibitor Withdrawal in Kidney Transplant Recipients. Transplantation Proceedings 48(3): 790-793, 2017

Immunosuppression with mammalian target of rapamycin inhibitor and incidence of post-transplant cancer in kidney transplant recipients. Nephrology, Dialysis, Transplantation 31(8): 1360-1367, 2017

Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients. American Journal of Transplantation 8(7): 1384-1392, 2008

Conversion to mammalian target of rapamycin inhibitors in kidney transplant recipients with de novo cancers. Oncotarget 8(27): 44833-44841, 2017

Mammalian Target of Rapamycin Inhibitors and Clinical Outcomes in Adult Kidney Transplant Recipients. Clinical Journal of the American Society of Nephrology 11(10): 1845-1855, 2016

Clinical outcomes in kidney transplant recipients receiving long-term therapy with inhibitors of the mammalian target of rapamycin. American Journal of Transplantation 12(2): 379-387, 2012

A systematic review of conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitors for maintenance immunosuppression in kidney transplant recipients. American Journal of Transplantation 14(9): 2106-2119, 2015

The effect of mammalian target of rapamycin inhibition on T helper type 17 and regulatory T cell differentiation in vitro and in vivo in kidney transplant recipients. Immunology 144(1): 68-78, 2015

Low-dose calcineurin inhibitor regimen combined with mammalian target of rapamycin inhibitors preserves kidney functions in renal transplant recipients without allograft nephropathy. Transplantation Proceedings 42(9): 3513-3516, 2011

Association between chronic periodontal disease and left ventricular hypertrophy in kidney transplant recipients. Transplantation 80(1): 3-5, 2005

Effect of mammalian target of rapamycin inhibitors on cytomegalovirus infection in kidney transplant recipients receiving polyclonal antilymphocyte globulins: a propensity score-matching analysis. Transplant International 29(11): 1216-1225, 2016

Left ventricular hypertrophy in pediatric kidney transplant recipients: long-term follow-up study. Pediatric Transplantation 10(7): 811-815, 2006

Effect of sirolimus on left ventricular hypertrophy in kidney transplant recipients: a 1-year nonrandomized controlled trial. American Journal of Kidney Diseases 52(2): 324-330, 2008